PACTR201110000274327招募中未知
Immunization with peptide-mix and adjuvant. A vaccine to induce cellular immunity against HIV-1
Statens Serum Institut (Helle Bossen Konradsen)0 个研究点目标入组 20 人开始时间: 2011年2月2日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Year(s) 至 50 Year(s)（—）
- 性别
- All
入选标准
- •1. HIV - 1 seropositive with measurable viral load > 10e3 copies/ml and CD4+Tcell count > 400 CD4+cell/ul
- •2. Not in Antiretroviral therapy (>1year)
- •3. male or female aged between 18 - 50 years
- •4. Normal values for the area of liver and kidney enzymes, blood cell count with differential counts (eg white blood cells, lymphocytes, platelets/thrombocytes) and Hemoglobin
- •5. Expected to follow instructions
- •6. Written informed consent after oral and written information
排除标准
- •1. Vaccinated with other vaccines within 3 months before the first vaccination
- •2. Treated with immune modulating medicine within 3 months before the first immunization
- •3. Other important active chronic infectious diseases likely to influence the HIV-1 infection, like HIV-2,HBV, HCV adn TB
- •4. Significant medical disease as judged by the investigators, for example, severe asthma/COLD, badly regulated heart disease, insulin dependent diabete mellitus
- •5. Severe allergy or earlier analphylactic reactions
- •6. Active autoimmune disease
- •7. Simultaneous treatment with other experimental drugs
- •8. Laboratory parameters outside the 'normal' range for teh area and which are considered clinically significant
- •9. Pregnancy
研究者
相似试验
已完成
1 期
Phase I/II study of a novel peptide vaccination therapy, CDCA1 and KOC1, for previously treated advanced non-small-cell lung cancerpreviously treated advanced non-small-cell lung cancerJPRN-UMIN000005087Showa University School of Medicine26
进行中（未招募）
1 期
Anti-tumoral vaccination of melanoma patients with peptides associated with GM-CT-01, a vegetal derived sugar that binds to and blocks galectin, a protein produced by tumor cells that inhibits immune cells.Metastatic melanomaMedDRA version: 14.0Level: LLTClassification code 10025651Term: Malignant melanoma excisionSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 14.0Level: LLTClassification code 10027150Term: Melanoma malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10042550Term: Superficial spreading melanoma stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10029488Term: Nodular melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10025662Term: Malignant melanoma of skin of scalp and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10040891Term: Skin melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10056768Term: Malignant melanoma of skin of lower limb, incl hipSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10048434Term: Melanoma malignant aggravatedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10042548Term: Superficial spreading melanoma in situSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10025652Term: Malignant melanoma in situSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-018638-29-BECentre du Cancer des Cliniques Universitaires Saint-Luc6
进行中（未招募）
1 期
Phase I/II study of peptide vaccination associated with tumoral immunomodulation with proinflammatory cytokines and imiquimod in patients with advanced metastatic melanomaEUCTR2010-020435-40-BECentre du Cancer3
已完成
1 期
A phase I/II study for peptides cocktail vaccine in patients with progressive or recurrent malignant glioma.Malignant gliomaJPRN-UMIN000012774Department of Neurosurgery, Keio University School of Medicine20
已完成
1 期
Phase I study of peptide-cocktail vaccination for HCV-positive patients with liver cancer who have undergone radical therapy.liver cancerJPRN-UMIN000003773Kurume University Cancer Vaccine Center3